Around 4,500 people living with advanced lung cancer are set to benefit from the new PBS listing of a checkpoint immunotherapy. Nivolumab (Opvido) has been listed on the PBS for locally advanced or metastatic non-small cell lung cancer and advanced (stage IV) clear cell variant renal cell carcinoma. The move to reimburse the drug represents ...
Lung Foundation welcomes new option for advanced lung cancer
3 Aug 2017